 Artist: Hilary Duff: mp3 download Genre(s): Dance: Pop Pop Rock: Pop-Rock Discography:  With Love (Remixes) CDS Year: 2007 Tracks: 7  Dignity Year: 2007 Tracks: 14  Most Wanted Year: 2005 Tracks: 13  Our Lips Are Sealed Year: 2004 Tracks: 3  Hilary Duff Year: 2004 Tracks: 20  Metamorphosis Year: 2003 Tracks: 13  Santa Claus Lane Year: Tracks: 11  Girl Can Rock Year: Tracks: 15 Hilary Duff first made a refer for herself on the tremendously successful Disney Channel/ABC Kids prove Lizzie McGuire, which she parlayed into careers as a pop vocaliser and film actress. Like nigh overnight successes, Duff gainful her dues for a few old age earlier her swelled check. Appearances in the 1997 women's Western True Women, 1998's Casper (as the Friendly Ghost's human friend Wendy), and 1999's The Soul Collector paved the way for her best-known purpose. Lizzie McGuire, which chronicled the ups and downs of jr high school schooler Lizzie's life with live-action and animated clips, debuted in 2001 and identical speedily became a brobdingnagian excise with the preteenager correct. Aside from the show's unique arrange, unitary of the principal reasons for its success was Duff herself. As Lizzie, she was pretty, funny, and voguish, exactly non intimidatingly so; she had 2 topper friends, Gordo and Miranda, so she wasn't super-popular or an castaway; and she was positive sufficiency to do her own affair, just noneffervescent vulnerable sufficiency to receive crushes on undoable boys. At the same time Lizzie was taking off, Duff too appeared in the indie celluloid Human Nature, reflecting her continuing big-screen aspirations. Lizzie McGuire manic disorder continued through 2002, and Duff began her first steps toward her telling career with the sung dynasty "Father Christmas Claus Lane," which appeared on the soundtrack to The Santa Clause 2, as well as her take in Christmas album, also named Santa Claus Lane. That year, yield terminated on Lizzie McGuire, freeing up Duff to follow other opportunities. Episodes of the show continued to campaign into 2003, just by that sentence Duff had begun to move on, appearing in the stripling spy moving picture Agent Cody Banks and playing Lizzie one last time in The Lizzie McGuire Movie, where strangely sufficiency, she goes to Italy and is mistaken for a stripling pop star topology. The soundtrack to the picture prove also featured several songs by Duff, including the singles "Wherefore Not" and "I Can't Wait," which were both successes in their have right; the soundtrack went pt in summer 2003. Around that meter, Metamorphosis, Duff's bona fide debut as a isaac M. Singer, was released. The album had a hipper and more eclecticist legal than whatever of the corporeal she had been granted antecedently, and helped establish her as a personality outside of her Lizzie McGuire fame. The album charted number two on the Billboard cc on the week of its freeing, and its single "So Yesterday" topped the pop singles graph to begin with that summer. Duff's omnipresence in 2003 continued with appearances at that year's MTV Video Music Awards and the Nickelodeon Kids Choice Awards, where she recognised Lizzie McGuire's prize for Favorite TV Show. She too appeared in that year's cinema Cheaper by the Dozen and embarked on a circuit that fall. 2004 was just now as meddling for Duff. She appeared in movies like A Cinderella Story, Agent Cody Banks, and Raise Your Voice, and besides released her self-titled second track record album, which exchanged the indifferent featheriness of Metabolism for an anthemic rock-pop style coherent with efforts from Ashlee Simpson and Avril Lavigne. The record continued to conformation Duff's populace part, which was a continually evolving dynamo of stigmatisation, figure, and teenaged ambition. Released on September 28th (her seventeenth birthday), Hilary Duff eventually peaked at figure iI on both the Billboard two century and the Top Internet Albums charts, and helped Hilary net profit "Near Searched by Kids and Teens on AOL" honors and more Nickelodeon Kids Choice Awards. Publicity for the album continued into 2005. That June, The Perfect Man debuted; in a bit of hotshot cast, it featured Heather Locklear as Duff's unlucky-in-love mother. In July, Duff started preparing for the August sack of Near Wanted. The accumulation included troika new songs -- including the single "Wake Up," written by Benji and Joel Madden from Good Charlotte -- as well as remixed versions of past Hilary hits like "So Yesterday" and "Come Clean." There was besides the Near Wanted tour, which stretched into September, termination just in time for her 18th birthday. By this point, the Hilary Duff promotional material machine was in overdrive: her site offered a pay-as-you-go mobile speech sound branded with her identify and bundled with Hilary-themed ringtones and wallpapers. During 2006, Duff worked on the films War Inc. and Corporeal Girls, and besides establish time to work on her quartern album, Self-worth, which was elysian in character by her breakup with Joel Madden. Dignity was released in spring 2007. |
Wednesday 3 September 2008
Download Hilary Duff mp3
Friday 15 August 2008
Edinburgh festival classical music review: Ysa�e Quartet
The odor of coffee tree, and a Haydn quartet: hard not to feel that the first daybreak chamber concert of the Edinburgh International festival was offering an oasis of civilisation in an otherwise chaotic city. The Ysa�e Quartet too supplied music to stir up the einstein up. Even the Haydn was unlawful: the C major Quartet, Op 54 No 2, which, with its through-composed middle movements and slow, serene closing curtain, subverts the usual classical pattern.
For most, nevertheless, the find will have been Szymanowski's Quartet No 2, written in 1927. Its endorsement and third base movements register the composer in proudly Polish mode: the former is a rough-edged dance driven as if by clockwork, the latter grows out of a contemplative folk-like psychogenic fugue. But the first effort is the most intriguing. It begins with a whispered, poker-faced buzz from the inner instruments, spell the low gear violin and cello tissue an angular melody or so them, and nods simultaneously towards the soft-grained textures of French impressionism and the blunt emotionality of German expressionism; perhaps the two are not so far apart.
Warm-toned in the Haydn, mercurially vivid in the Szymanowski, the players became benign automatons for Stravinsky's Three Pieces, putting a stop on almost all vibrato; these spare slight pieces seemed to deal the clockwork aspect of the Szymanowski to its logical conclusion.
Last came Debussy's Quartet, inevitably a signature work for any French tout ensemble, particularly one and only that shares a name with the work's creators (the original Ysa�e Quartet gave the premiere in 1893). From the impatient opening, through the seamlessly turning cycles of the second move to a finale that seemed a whistlestop retrospective of all that had gone earlier, this was a riveting performance.
More info
Thursday 7 August 2008
FDA Rejects Schering-Plough's Anaesthetic Drug Sugammadex NDA
�The U.S. FDA has issued a non-approvable letter to Schering-Plough regarding the U.S. firm's New Drug Application (NDA) for sugammadex sodium. The product (likewise marketed under the brand Bridion) is a selective relaxant binding agent that reverses the effects of neuromuscular hinder by rocuronium in general anaesthesia. In a press statement, Schering-Plough has aforesaid that the FDA's concerns over the drug ar related to hypersensitivity or allergic reactions. No issues related to the efficacy of the drug have been mentioned by the agency. Schering-Plough acquired the drug after purchasing biopharmaceutical firm Organon Biosciences in November 2007, and has since touted the experimental product as one of its main gains. Schering has noted that the product is the first base innovation in two decades in the anaesthesia segment, and has committed to working with the FDA to dissolve the issues behind the rejection.
Meanwhile, the company's cholesterol production Vytorin was once once more under the spotlight. The U.S. House Energy and Commerce Committee has asked the FDA to print details of the findings on a study conducted to examine the product's cancer risk, Reuters reports. The field found a higher cancer risk associated with patients taking Vytorin at 39 and with patients on a placebo at 23 in the closely monitored trial.
Outlook and Implications
The rejection will be a setback for Schering-Plough - more in terms of investor confidence in the short term. The company has had a serial of run-ins with regulatory agencies since cholesterol do drugs Vytorin and Zetia (ezetimibe/simvastatin and ezetimibe) were linked to potency adverse safety issues. However, the development is evenhandedly surprising given that an FDA panel gave it a confident go-ahead in March. However, although the committee gave its commendation, it did cite concerns over allergy reactions. Nevertheless, the approval was unanimous. Further, the company gained European Commission approval for marketing the drug in the European Union (EU) as Bridion. For Schering-Plough, the ontogeny will delay the realization of the benefits the U.S. strong obtained when it acquired Organon Biosciences.
From a regulatory linear perspective, the intersection is the fourth in the heel of jilted applications from the FDA that is associated with Big Pharma firms. Notably, the regulative agency had rejected Merck & Co's (U.S.) Cordaptive/Tredaptive (nicotinic acid/laropiprant), Merck and Schering-Plough's respiratory combination dose Claritin and Singulari (loratidine and montelukast), and Eli Lilly's (U.S.) long-acting version of schizophrenic psychosis drug Zyprexa (olanzapine), principally due to safety concerns. The rejection will put the agency's conservative coming to NDAs under the spotlight. Global pharmaceutical major league have already noted that the number of FDA approvals has reduced, triggered by the withdrawal of Merck's Vioxx (rofecoxib) over safety concerns. The office is under increasing pressure from the U.S. authorities, leading to a tightening of criteria for NDA approvals.
http://www.schering-plough.com
View drug information on Claritin RediTabs; Vioxx; Zyprexa.
More information
Meanwhile, the company's cholesterol production Vytorin was once once more under the spotlight. The U.S. House Energy and Commerce Committee has asked the FDA to print details of the findings on a study conducted to examine the product's cancer risk, Reuters reports. The field found a higher cancer risk associated with patients taking Vytorin at 39 and with patients on a placebo at 23 in the closely monitored trial.
Outlook and Implications
The rejection will be a setback for Schering-Plough - more in terms of investor confidence in the short term. The company has had a serial of run-ins with regulatory agencies since cholesterol do drugs Vytorin and Zetia (ezetimibe/simvastatin and ezetimibe) were linked to potency adverse safety issues. However, the development is evenhandedly surprising given that an FDA panel gave it a confident go-ahead in March. However, although the committee gave its commendation, it did cite concerns over allergy reactions. Nevertheless, the approval was unanimous. Further, the company gained European Commission approval for marketing the drug in the European Union (EU) as Bridion. For Schering-Plough, the ontogeny will delay the realization of the benefits the U.S. strong obtained when it acquired Organon Biosciences.
From a regulatory linear perspective, the intersection is the fourth in the heel of jilted applications from the FDA that is associated with Big Pharma firms. Notably, the regulative agency had rejected Merck & Co's (U.S.) Cordaptive/Tredaptive (nicotinic acid/laropiprant), Merck and Schering-Plough's respiratory combination dose Claritin and Singulari (loratidine and montelukast), and Eli Lilly's (U.S.) long-acting version of schizophrenic psychosis drug Zyprexa (olanzapine), principally due to safety concerns. The rejection will put the agency's conservative coming to NDAs under the spotlight. Global pharmaceutical major league have already noted that the number of FDA approvals has reduced, triggered by the withdrawal of Merck's Vioxx (rofecoxib) over safety concerns. The office is under increasing pressure from the U.S. authorities, leading to a tightening of criteria for NDA approvals.
http://www.schering-plough.com
View drug information on Claritin RediTabs; Vioxx; Zyprexa.
More information
Friday 27 June 2008
Zero 7
Artist: Zero 7
Genre(s):
Easy Listening
Electronic
Trip-Hop
Techno
Discography:
When It Falls
Year: 2004
Tracks: 11
Distractions
Year: 2002
Tracks: 6
AnotherLateNight
Year: 2002
Tracks: 16
Simple Things
Year: 2001
Tracks: 12
In The Waiting Line
Year: 2001
Tracks: 6
The manpower behind U.K. soulfulness turnout Zero 7 -- producers Henry Binns and Sam Hardaker -- launched their careers in the music manufacture as tea boys at a London recording studio. Soon later on, notwithstanding, both were in the fatheaded of action, working alongside a string of well-known British musicians such as the Pet Shop Boys and Robert Plant. They spent the topper character of the nineties honing their production skills behind the scenes. Then, later on taking on the identify of a nightspot in Honduras, the distich step by step began unleashing their possess ideas onto an unsuspecting populace. First came a couple of remixes; Radiohead's "Mounting Up the Walls" and Terry Callier's "Dearest Theme from Spartacus." In 1999, Zero 7 released their starting time EP, the fittingly titled EP 1. Only a smattering of copies were made and they sold out in a matter of years. A similar fate hoped-for their second gear release, EP 2. Their starting time record album, Simple Things, came out amid practically salivating from the media in mid-2001. A aggregation of mellow soul, acidulent jazz, and funk tracks, the album carried collaborations with well-thought-of vocalists Mozez, Sia Furler, and Sophie Barker. Their soph endeavour, When It Falls, appeared in March 2004, and it was followed 2 years afterwards by Garden, which included contributions from longtime favourite Sia as substantially as Swedish star José González.
Thursday 19 June 2008
Pierce on Losing Bond: "I Didn't See That Coming"
Actresses aren't the only ones dealing with ageism in Hollywood. Pierce Brosnan is feeling its effects as well -- and it hurts.
While Sean Connery and Roger Moore played James Bond well into their 50s (58 and 53, respectively), Pierce was revoked of his license to kill at age 51 for the then-37-year-old Daniel Craig, which definitely took him by surprise.
"I didn't see that coming," the actor tells Parade magazine. "I never thought of myself as being too old. It was startling to hear such things said about oneself, especially when you thought you were going down that particular avenue and then the door gets slammed in your face."
The Irish stud knew his days as 007 were numbered, but figured producers would give him one last hurrah before passing the torch.
"I thought we were going to do a fifth film," he says. "And I was going to take a gracious bow off the stage. Instead of that you're just told, 'Goodbye.'"
Now 55, Pierce has since traded in tuxes for t-shirts, living with wife Keely and their sons Dylan, 11, and Paris, 7, in Hawaii. His next flick, a big-screen production of Mamma Mia! hits theaters July 18, and he has made peace with his Bond axing.
"That's the way it goes down in life," he says. "It's as hard and as fast as that."
See Also
Saturday 14 June 2008
Less Gold For 'Prince'
Like last week, the top film at the box office, having already brought in less than analysts had predicted on Sunday, when the studio announced its weekend estimate, earned even less than that when the actual ticket-sales figures were finally disclosed on Monday. Although The Chronicles of Narnia: Prince Caspian was not the unmitigated disaster that Speed Racer was last week, the movie's $55.03 million take was $1.6 million below Sunday's estimate. By contrast, the No. 2 film, Iron Man earned $31.84 million, somewhat more than the $31.20 million that the studio had calculated. Overall, the weekend's top 12 films grossed $125.8 million, 28 percent below last year's $173.6 million for the comparable weekend.
The top ten films over the weekend, according to final figures compiled by Media by Numbers (figures in parentheses represent total gross to date): 1. The Chronicles of Narnia: Prince Caspian,
See Also
Sunday 8 June 2008
Steroids film examines obsession with winning
NEW YORK (Reuters) - A new documentary that takes a wide-ranging look at steroid abuse suggests an American culture of winning at all costs is at odds with its public condemnation of the performance-enhancing drugs.
"Bigger, Stronger, Faster*," which opened in the United States on Friday, features interviews with gym junkies, medical experts, U.S. lawmakers and athletes such as former sprinters Carl Lewis and Ben Johnson and cyclist Floyd Landis.
But the documentary from the producers of Michael Moore's hits "Fahrenheit 9/11" and "Bowling for Columbine" also includes comical and touching first-person accounts by director Chris Bell and his confessed steroid-using weightlifting and bodybuilding brothers.
"I am basically looking at all the hypocrisy surrounding steroids," said Bell, 35, who chronicles growing up idolizing and emulating "winners" such as Sylvester Stallone and Arnold Schwarzenegger.
"Seeing all these larger-than-life heroes, I wanted to be like them and I did not know they were using steroids," he said. "Nobody wants to talk about steroids and I knew my brothers would tell me the truth so I started with them."
The film broadens its scope when it explores why steroids have a bad name -- they have legitimate medical purposes but it is illegal to use them without a prescription in the United States -- and why America obsesses over body image.
"More scrupulously reported than your average Michael Moore film but every bit as entertaining, 'Bigger, Stronger, Faster*' is as commercial as documentaries come," said Variety magazine.
The film suggests that part of the problem is a penchant for making scapegoats out of athletes like former Canadian sprinter Ben Johnson when in fact steroids can be traced back to American Olympic teams in the 1950s and 1960s.
"Bigger, Stronger, Faster*," which opened in the United States on Friday, features interviews with gym junkies, medical experts, U.S. lawmakers and athletes such as former sprinters Carl Lewis and Ben Johnson and cyclist Floyd Landis.
But the documentary from the producers of Michael Moore's hits "Fahrenheit 9/11" and "Bowling for Columbine" also includes comical and touching first-person accounts by director Chris Bell and his confessed steroid-using weightlifting and bodybuilding brothers.
"I am basically looking at all the hypocrisy surrounding steroids," said Bell, 35, who chronicles growing up idolizing and emulating "winners" such as Sylvester Stallone and Arnold Schwarzenegger.
"Seeing all these larger-than-life heroes, I wanted to be like them and I did not know they were using steroids," he said. "Nobody wants to talk about steroids and I knew my brothers would tell me the truth so I started with them."
The film broadens its scope when it explores why steroids have a bad name -- they have legitimate medical purposes but it is illegal to use them without a prescription in the United States -- and why America obsesses over body image.
"More scrupulously reported than your average Michael Moore film but every bit as entertaining, 'Bigger, Stronger, Faster*' is as commercial as documentaries come," said Variety magazine.
The film suggests that part of the problem is a penchant for making scapegoats out of athletes like former Canadian sprinter Ben Johnson when in fact steroids can be traced back to American Olympic teams in the 1950s and 1960s.
Subscribe to:
Posts (Atom)